Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. METHODS: We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab. Whole-exome sequencing was performed on tumors and matched blood samples. Somatic mutations and candidate neoantigens generated from these mutations were characterized. Neoantigen peptides were tested for the ability to activate lymphocytes from ipilimumab-treated patients. RESULTS: Malignant melanoma exomes from 64 patients treated with CTLA-4 blockade were characterized with the use of massively parallel sequencing. A discovery set consisted of 11 patients who derived a long-term clinical benefit and 14 patients who derived a minimal benefit or no benefit. Mutational load was associated with the degree of clinical benefit (P=0.01) but alone was not sufficient to predict benefit. Using genomewide somatic neoepitope analysis and patient-specific HLA typing, we identified candidate tumor neoantigens for each patient. We elucidated a neoantigen landscape that is specifically present in tumors with a strong response to CTLA-4 blockade. We validated this signature in a second set of 39 patients with melanoma who were treated with anti-CTLA-4 antibodies. Predicted neoantigens activated T cells from the patients treated with ipilimumab. CONCLUSIONS: These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“external validation using the Snyder cohort substantiated the model’s robust performance characteristics, maintaining exceptional predictive capability for immunotherapeutic response assessment (AUC = 0.769, AUPRC = 0.722, Fisher’s exact test P = 2.42 × 10−5; Fig. 4, A to C).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [38]
In the citing paper
“As both classes of HLA molecule have previously been shown to have a central role in CD8+ and CD4+ T cell immunity43–49”
From Identification of bacteria-derived HLA-bound peptides in melanoma (2021) · cites this paper as [47]
In the citing paper
“Indeed, as mentioned in the previous section, both PD-1 and CTLA-4 blockades are more effective in tumors that are infiltrated by T cells or that have high mutation rates and are therefore more immunogenic prior to treatment (86–88).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [87]
In the citing paper
“This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [87]
In the citing paper
“In keeping with a more complex genomic landscape and a larger burden of clonal or sub-clonal co-drivers, multiple clinical studies have identified TP53 co-alterations as a negative prognostic marker in EGFR-mutant LUAD and a consistent predictor of worse clinical outcomes following EGFR TKI therapy72, 73, 111–116.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [111]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Above normal 2 (18) 5 (36) 3 (12) 3 (21)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288 · cited 1×
“Not available 1 (9) 1 (7) 14 (56) 2 (14)”
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810 · cited 1×
“Not available 1 (9) 1 (7) 14 (56) 2 (14)”
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Research works printed but not linked: 1
- Wolchok JD, 2010, Cancer Immun, 10, 9
Cited by
Items 301–400 of 460
Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Schulze, K., Nault, J.-C., & Villanueva, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.035 · Cited by 317
Chen, C.-C., Feng, W., Lim, P. X., Kass, E. M., & Jasin, M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050502 · Cited by 317
“…this, the clinical benefit of immune checkpoint blockade therapies has been observed in cancers with a high mutational burden resulting from environmental exposure, including melanoma and non-small-cell lung cancer (Hugo et al. 2016, Rizvi et al. 2015, Snyder et al. 2014, Van Allen et al. 2015).”
BackgroundPrecision medicine for metastatic breast cancer—limitations and solutions
Arnedos, M., Vicier, C., Loi, S., Lefebvre, C., Michiels, S., Bonnefoi, H., & Andre, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.123 · Cited by 317
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Wang, S., He, Z., Wang, X., Li, H., & Liu, X.-S. (2019) · eLife · doi:10.7554/elife.49020 · Cited by 312
“, 2014; Shukuya and Carbone, 2016), TMB (Rizvi et al., 2015; Snyder et al., 2014), DNA mismatch repair deficiency (Le et al.”
BackgroundTissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Fancello, L., Gandini, S., Pelicci, P. G., & Mazzarella, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0647-4 · Cited by 310
“load assessment [14], is technically less challenging and less expensive and may represent a better suited predictive biomarker for immunotherapy response.”
BackgroundInfluentialCombining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 309
“In our recent study (56), basal expression levels of the Azainduced viral defense gene signature in tumor samples correlate with long-term benefit in patients with advanced melanoma treated with the immune checkpoint inhibitor anti-CTLA-4 (63).”
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307
Self-citationFunctional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., Dousset, L., Pham-Ledard, A., Prey, S., Beylot-Barry, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212257 · Cited by 306
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., Morris, L. G. T., Riaz, N., Lenz, T. L., & Chan, T. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0639-4 · Cited by 306
Self-citationAntagonists of PD-1 and PD-L1 in Cancer Treatment
Lipson, E. J., Forde, P. M., Hammers, H.-J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.013 · Cited by 306
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Ali, H. R., Glont, S.-E., Blows, F. M., Provenzano, E., Dawson, S.-J., Liu, B., Hiller, L., Dunn, J., Poole, C. J., Bowden, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv192 · Cited by 304
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
“This could be a reason why tumors with neoantigens respond better to immune checkpoint and tumors with low mutational burden are nonresponsive[108,109].”
BackgroundSelf-citationKohlhapp, F. J., & Kaufman, H. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2667 · Cited by 303
“Recent data from patients treated with T-cell checkpoint inhibitors have also suggested the emergence of neoantigens from established tumors as an important component of the immune response to treatment (36).”
ResultThe efficacy of anti‐PD‐1 agents in acral and mucosal melanoma
Shoushtari, A. N., Munhoz, R. R., Kuk, D., Ott, P. A., Johnson, D. B., Tsai, K. K., Rapisuwon, S., Eroglu, Z., Sullivan, R. J., Luke, J. J., et al. (2016) · Cancer · doi:10.1002/cncr.30259 · Cited by 302
“In patients with cutaneous melanoma who received ipilimumab, a higher mutational burden was associated with improved survival.(23,24) In a recent phase 2 trial of nivolumab in patients with mismatch repair (MMR)-deficient carcinomas and MMRproficient colorectal adenocarcinomas, MMR-deficient cancers had a significantl…”
BackgroundSelf-citationImmuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 301
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Morris, L. G. T., Riaz, N., Desrichard, A., Şenbabaoğlu, Y., Hakimi, A. A., Makarov, V., Reis-Filho, J. S., & Chan, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.7067 · Cited by 299
Self-citationPD-1 and PD-L1 antibodies in cancer: current status and future directions
Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 298
“An association between mutational load and response to immune checkpoint inhibitors was first observed in studies of ipilimumab in advanced melanoma [86, 87].”
BackgroundLin, Z., Wu, Y., Xu, Y., Li, G., Li, Z., & Liu, T. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01650-5 · Cited by 297
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“, a high mutational load of the tumor cells [3,4], the presence of neoantigens [5,6], microsatellite instability [7,8], and host factors, i.”
BackgroundUrea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
Lee, J. S., Adler, L., Karathia, H., Carmel, N., Rabinovich, S., Auslander, N., Keshet, R., Stettner, N., Silberman, A., Agemy, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.019 · Cited by 296
“While the association between mutational burden and ICT response was observed in some datasets (Rizvi et al., 2015; Rosenberg et al., 2016; Snyder et al., 2014), there are quite a few datasets (Hugo et al.”
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
Immunotherapy, Inflammation and Colorectal Cancer
Lichtenstern, C. R., Ngu, R. K., Shalapour, S., & Karin, M. (2020) · Cells · doi:10.3390/cells9030618 · Cited by 294
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C., Chang, E., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 289
Lee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
“It will be interesting to explore whether these limitations in fl uence the predictive value of tumor mutation load, which has been shown to predict clinical bene fi t of immune checkpoint blockade in multiple cancers, including melanoma 61 – 63 .”
Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285
“A recent study demonstrating that patients responding to CTLA-4 inhibition for the treatment of melanoma were more likely to have genetically heterogeneous tumors that expressed a panel of antigenic peptides indicates that tumor immunogenicity modulates the efficacy of checkpoint blockade (8).”
ResultMismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Lee, V., Murphy, A., Le, D. T., & Diaz, L. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0046 · Cited by 283
Shain, A. H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, J. Z., Chung, J., Wang, N. J., Kakavand, H., Mann, G. J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3382 · Cited by 283
Pembrolizumab for the treatment of non-small cell lung cancer
Lim, S. H., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1145652 · Cited by 282
“[41] Candidate neoepitopes were identified by mutational analysis and the presence of neoepitope signature peptides was correlated strongly with survival.[41] 402 S.”
BackgroundTargeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 281
“The correlation of tumor mutation burden with response for melanoma is logical but there are outliers in terms of precise association and the features of mutation encoded neo-antigens leading to functional immune responses are not clearly established [76-78].”
BackgroundSelf-citationPrecision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 278
Gajewski, T. F., Corrales, L., Williams, J., Horton, B., Sivan, A., & Spranger, S. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 278
“A recent report has suggested that patients who failed to derive clinical benefit from the antiCTLA-4 mAb ipilimumab might have fewer mutations and lack the antigens present in the tumors of responding patients [20].”
BackgroundThe genomic landscape of breast cancer and its interaction with host immunity
Luen, S., Virassamy, B., Savas, P., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 277
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276
Painter, C. A., Jain, E., Tomson, B. N., Dunphy, M., Stoddard, R. E., Thomas, B. S., Damon, A. L., Shah, S., Kim, D., Gómez Tejeda Zañudo, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0749-z · Cited by 276
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 275
“Therefore, the neo-antigens are considered ideal targets for immunotherapy and their detection could be a good biomarker to predict the efficiency of immune checkpoint inhibitors including both anti-PD-1 (programmed death-1) and anti-CTLA4 monoclonal antibodies (MoAbs) [28, 29].”
BackgroundPollack, S. M., He, Q., Yearley, J. H., Emerson, R., Vignali, M., Zhang, Y., Redman, M. W., Baker, K. K., Cooper, S., Donahue, B., et al. (2017) · Cancer · doi:10.1002/cncr.30726 · Cited by 274
Oweida, A., Hararah, M. K., Phan, A., Binder, D., Bhatia, S., Lennon, S., Bukkapatnam, S., Van Court, B., Uyanga, N., Darragh, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 274
“Predictive indicators of positive response to immune therapy include the presence of tumorinfiltrating lymphocytes, expression of PD-L1 on tumor cells, and high mutation burden (3, 35, 36).”
BackgroundFreed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
“Neoantigen-specific CD8 T lymphocytes, which recognize cognate antigen presented in the context of MHC class I, are thought to underlie the success of current immune-based strategies (Snyder et al., 2014).”
BackgroundTherapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273
“Multiple cancer cell–intrinsic mechanisms have been identified, including low neoantigen load (2, 3, 10, 11), loss of antigen presentation (12, 13), loss of HLA heterozygosity (14, 15), impaired response or prolonged exposure to IFNγ (16–19), and activation of certain oncogenic pathways/signatures (20–22), as well as…”
BackgroundSystems immunology: just getting started
Davis, M. M., Tato, C. M., & Furman, D. (2017) · Nature Immunology · doi:10.1038/ni.3768 · Cited by 273
Duffy, M. J., & Crown, J. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.303644 · Cited by 273
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.014 · Cited by 259
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Future directions in the treatment of osteosarcoma
Bishop, M. W., Janeway, K. A., & Gorlick, R. (2016) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000298 · Cited by 268
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
“In this setting, genetic deletion of specific epitopes recognized by CAR T cell clones facilitates tumor escape (Sotillo et al., 2015).”
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Dafni, U., Michielin, O., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V, Karlis, D., Besser, M. J., Haanen, J., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 263
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Thomas, A., Routh, E. D., Pullikuth, A., Jin, G., Su, J., Chou, J. W., Hoadley, K. A., Print, C., Knowlton, N., Black, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490854 · Cited by 262
Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 262
“Cancer Immunol Res; 7(5) May 2019 Cancer Immunology Research 792”
BackgroundInfluentialNovel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Fabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
“Increased neoantigenic burden within tumor cells has been linked to PD-1/PD-L1 therapeutic response in several indications, however the high cost and significant time associated with neo-antigen discovery/prediction necessitates a more clinically relevant means of predicting response (7,10-12).”
BackgroundOliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B., Mesia, R., & Siu, L. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy507 · Cited by 260
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Chowell, D., Yoo, S.-K., Valero, C., Pastore, A., Krishna, C., Lee, M., Hoen, D., Shi, H., Kelly, D. W., Patel, N., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01070-8 · Cited by 260
Self-citationDeterminants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R., Byrne, F., Horswell, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 260
Challenges in developing personalized neoantigen cancer vaccines
Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00937-y · Cited by 258
Biomarkers for immunotherapy response in head and neck cancer
Gavrielatou, N., Doumas, S., Economopoulou, P., Foukas, P. G., & Psyrri, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101977 · Cited by 256
Kitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010240 · Cited by 256
“A correlation between the amount of this gene mutation and the effect of ICIs has already been reported in malignant melanoma and lung cancer [32,33], and a strong effect is expected in oral cancer.”
BackgroundBiomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer: A Review
Sacher, A. G., & Gandhi, L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0639 · Cited by 255
Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx029 · Cited by 255
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 255
Big data in basic and translational cancer research
Jiang, P., Sinha, S., Aldape, K., Hannenhalli, S., Sahinalp, C., & Ruppin, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00502-0 · Cited by 254
“Gene alterations relevant to therapy decisions could involve diverse forms, including single-nucleotide mutations, DNA insertions, DNA deletions, copy number alterations, gene rearrangements, microsatellite instability and tumour mutational burden 78–80 .”
BackgroundWang, S., Jia, M., He, Z., & Liu, X.-S. (2018) · Oncogene · doi:10.1038/s41388-018-0245-9 · Cited by 254
“Currently known biomarkers of response to anti‐PD-1/PD-L1 therapies include: PD-L1 expression [17, 18], tumor mutational load [19, 20], DNA mismatch repair (MMR) deficiency [21] and CD8 T-cell intensity [22, 23].”
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-24100-1_2 · Cited by 246
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236
Wang, Z., Zhao, J., Wang, G., Zhang, F., Zhang, Z., Zhang, F., Zhang, Y., Dong, H., Zhao, X., Duan, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1814 · Cited by 241
“The median TMB levels of patients with single mutations in DDR genes were 52 (TCGA) and 53 (ICGC), which were very different from the previously reported predictive TMB cut-off values (6,10,21,22).”
BackgroundMethodResultIdentification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Wang, Q. J., Yu, Z., Griffith, K., Hanada, K.-I., Restifo, N. P., & Yang, J. C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0188 · Cited by 240
“Although the presence of such immunologic activity in patients with cancer has been recognized for 20 years (9), recent data have shown that this activity is associated with clinical responses to checkpoint blockade with antibodies to CTLA-4 and PD-1 in patients with melanoma and non–small cell lung cancer (10, 11).”
BackgroundTCR contact residue hydrophobicity is a hallmark of immunogenic CD8 + T cell epitopes
Chowell, D., Krishna, S., Becker, P. D., Cocita, C., Shu, J., Tan, X., Greenberg, P. D., Klavinskis, L. S., Blattman, J. N., & Anderson, K. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500973112 · Cited by 239
“With the advent of tumor exome sequencing in immune therapy settings, we anticipate that immunogenicity models such as ANN-Hydro will be critical in identifying immunogenic neoantigens for tumor immune therapies (35, 36).”
MethodComprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Self-citationLearning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Immunotherapy for Breast Cancer: What Are We Missing?
Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2569 · Cited by 233
“Importantly, the mechanisms of actions of both CTLA-4 and PD-1/PD-L1 blocking mAb have been linked to activation or reinvigoration of neoepitope specific T cells in melanoma and lung cancer (31, 32).”
BackgroundWang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225
“We also expect that the combination may provide a better response to immune checkpoint therapy, because high basal levels of viraldefense genes correlate with better clinical outcomes after antiCTL4 immune checkpoint therapy (12, 49).”
BackgroundKarn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H. P., Huober, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.015 · Cited by 224
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Self-citationT cell regeneration after immunological injury
Velardi, E., Tsai, J. J., & van den Brink, M. R. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00457-z · Cited by 222
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
“This is in line with the correlation of response to checkpoint inhibitor therapy with tumor mutational burden (9, 10).”
ResultSade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
“performed on bulk tumor tissues taken from patients treated with anti-CTLA4, showed that high mutational load and neoantigens presented by the tumor cells, correlate with response to this therapy (41, 42).”
BackgroundA phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Rohaan, M. W., van den Berg, J. H., Kvistborg, P., & Haanen, J. B. A. G. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0391-1 · Cited by 196
“This has been demonstrated for lung cancer patients treated with anti-PD-1 therapy [40], melanoma patients treated with anti-CTLA-4 [41], and patients with mismatch repair deficient tumors across several cancer types with anti-PD-1 treatment [42, 43].”
BackgroundGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
“5, 23 21–34 Given the increasing appreciation for the role of neoantigens in responses to therapy, 35 we next performed in silico analysis of putative neoantigens in our cohort from WES data using the NetMHC3.”
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
“However, this correlation is weak at an individual tumor level, as the presence of mutations does not necessarily result in neoantigen formation, and multiple factors are involved in the presentation of antigens to elicit an immune response (32, 33).”
BackgroundFizazi, K., Drake, C. G., Beer, T. M., Kwon, E. D., Scher, H. I., Gerritsen, W. R., Bossi, A., den Eertwegh, A. J. M. V., Krainer, M., Houede, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.07.032 · Cited by 185
Panda, A., de Cubas, A. A., Stein, M., Riedlinger, G., Kra, J., Mayer, T., Smith, C. C., Vincent, B. G., Serody, J. S., Beckermann, K. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121522 · Cited by 181
Metadata
- Authors
- Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2189-2199
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4315319
- OpenAlex
- W2104885590
- Cited by
- 4,286
- References
- 37
- Citations by year
- 2026: 100 · 2025: 190 · 2024: 249 · 2023: 291 · 2022: 410 · 2021: 436 · 2020: 460 · 2019: 434 · 2018: 464 · 2017: 479 · 2016: 436 · 2015: 316 · 2014: 11
- FWCI
- 200.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009512, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- melanoma, CTLA-4 blockade, ipilimumab, tremelimumab, immune checkpoint inhibitors, neoantigens, somatic mutations, mutational load, predictive biomarkers, T cell activation, HLA typing, exome sequencing, clinical response prediction
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Histocompatibility Testing, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, High-Throughput Nucleotide Sequencing, Exome, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.